Growth hormone peptides

The fundamental challenge with growth hormone peptides isn't that they don't work — it's that most of them weren't designed to be used the way researchers currently use them. Compounds like CJC-1295 DAC and Ipamorelin emerged from pharmaceutical programs aimed at treating severe growth hormone deficiency, not optimizing body composition in healthy adults. The evidence gap between these original therapeutic contexts and current research applications is wide, and understanding that gap matters more than most dosing protocols acknowledge.

What Growth Hormone Peptides Are: Synthetic Mimics of a 44-Amino Acid Hormone

Growth hormone peptides are synthetic compounds designed to either mimic growth hormone-releasing hormone (GHRH) or stimulate growth hormone secretion through alternative pathways. Natural GHRH is a 44-amino acid peptide produced in the hypothalamus that signals the anterior pituitary to release growth hormone. Most research peptides in this class fall into two categories: GHRH analogs (like Sermorelin, Mod GRF 1-29, and CJC-1295) and growth hormone secretagogues (like GHRP-2, GHRP-6, Hexarelin, and Ipamorelin).

The GHRH analogs are modified versions of the first 29 amino acids of native GHRH — the bioactive fragment. These modifications typically aim to extend half-life beyond the roughly 7-minute window of natural GHRH. Tesamorelin is the only FDA-approved GHRH analog, indicated specifically for HIV-associated lipodystrophy, which gives us one of the few windows into controlled human data in this class.

The secretagogues work through a different mechanism entirely. They bind to the ghrelin receptor (growth hormone secretagogue receptor 1a, or GHSR1a), which exists throughout the central nervous system and peripheral tissues. Ghrelin itself is a 28-amino acid peptide hormone produced primarily in the stomach. The synthetic secretagogues are typically much shorter — GHRP-6 is a hexapeptide, Ipamorelin is a pentapeptide — and were designed to trigger growth hormone release without ghrelin's appetite-stimulating effects.

MK-677 (ibutamoren) belongs in this class but isn't technically a peptide. It's an orally bioavailable small molecule ghrelin mimetic, which makes it structurally distinct but functionally similar.

How These Compounds Signal Through Growth Hormone Axis Receptors

GHRH analogs bind to the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary. This is a G-protein-coupled receptor linked to adenylyl cyclase. Binding triggers a cascade: increased cyclic AMP, activation of protein kinase A, and ultimately transcription of the growth hormone gene and exocytosis of stored growth hormone. The modifications in synthetic analogs don't change this core mechanism — they extend duration of receptor occupancy by resisting degradation by dipeptidyl peptidase-4 (DPP-4), the enzyme that rapidly cleaves native GHRH.

CJC-1295 with DAC (Drug Affinity Complex) takes this further by adding a reactive group that binds to serum albumin, creating a depot effect that extends the half-life to roughly 6-8 days in human pharmacokinetic studies. This long duration changes the pharmacodynamic profile significantly — instead of pulsatile growth hormone release (which mimics natural physiology), you get sustained elevation of baseline growth hormone.

Growth hormone secretagogues work through GHSR1a, which is also a G-protein-coupled receptor but signals through a different pathway: primarily Gq-mediated phospholipase C activation, leading to increased intracellular calcium and growth hormone release. Importantly, GHSR1a is not exclusive to the pituitary — it's expressed in the hippocampus, hypothalamus, myocardium, adrenal glands, and elsewhere. This distribution explains some of the off-target effects seen in research: increased cortisol (adrenal GHSR1a activation), changes in feeding behavior (hypothalamic circuits), and potential cardiovascular effects.

The distinction between these pathways matters for synergy. GHRH analogs and secretagogues can be co-administered because they activate different receptors. This combination produces larger growth hormone pulses than either alone — demonstrated in multiple human studies dating back to the 1990s. The mechanism is straightforward: GHSR1a activation primes somatotrophs to be more responsive to GHRH signaling.

Once growth hormone is released, it acts directly on tissues expressing growth hormone receptors and indirectly through insulin-like growth factor 1 (IGF-1), which is synthesized primarily in the liver in response to growth hormone. IGF-1 LR3 and IGF-1 DES are direct IGF-1 analogs that bypass this axis entirely, which places them in a related but mechanistically distinct category.

Three Decades of Human Studies with Highly Variable Quality and Endpoints

The evidence base for growth hormone peptides spans from well-controlled pharmaceutical trials to uncontrolled observational research with significant methodological limitations. Starting with the highest-quality data: Tesamorelin has been studied in multiple Phase III trials for HIV-associated lipodystrophy, with over 800 participants across two primary studies. At 2 mg subcutaneous daily, it reduced visceral adipose tissue by approximately 15% compared to placebo over 26 weeks, with sustained effects through 52 weeks. Growth hormone and IGF-1 increased dose-dependently, and the compound was generally well-tolerated, though glucose parameters worsened slightly in a subset of participants.

Sermorelin has weaker human evidence. It was approved by the FDA in 1997 for diagnostic testing of growth hormone secretion and briefly marketed for pediatric growth hormone deficiency, but was discontinued in 2008 when the manufacturer stopped production. The published trials from that era show it increases growth hormone in a dose-dependent manner (typical doses: 1-2 mcg/kg subcutaneous), but there are no large, long-term trials examining body composition or functional outcomes in adults.

For Mod GRF 1-29 (also called CJC-1295 without DAC, or modified GRF 1-29), the human data is minimal. It's a modified version of Sermorelin with better DPP-4 resistance, but the published literature consists primarily of pharmacokinetic studies showing an extended half-life of approximately 30 minutes versus 7 minutes for native GHRH. There are no large controlled trials examining efficacy endpoints.

CJC-1295 with DAC has slightly more human data, largely from the original pharmaceutical development program. A 2006 study in healthy adults (n=18) demonstrated that a single 30-90 mcg/kg dose produced sustained elevation of growth hormone and IGF-1 for up to 14 days. Weekly dosing at 30 or 60 mcg/kg for 4 weeks increased lean body mass by approximately 1-2 kg with corresponding decreases in fat mass, though the trial was small and unblinded. Injection site reactions were common, and there were mild transient increases in blood glucose in some participants.

The growth hormone secretagogues have more extensive early-phase research but limited long-term data. GHRP-6 was studied in multiple human trials in the 1990s showing dose-dependent growth hormone release, with typical effective doses around 1 mcg/kg. Its appetite-stimulating effects (via ghrelin receptor activation) limited clinical development. GHRP-2 has similar data — it reliably stimulates growth hormone at doses of 0.5-1.5 mcg/kg IV or subcutaneous, but there are no large trials examining body composition changes over months.

Ipamorelin was designed to minimize the cortisol and prolactin increases seen with other secretagogues. A 2006 study in healthy older adults compared Ipamorelin (0.5 mg/kg IV) to GHRP-6 and GHRH. Ipamorelin increased growth hormone 4-fold over baseline without significantly affecting cortisol or prolactin, whereas GHRP-6 increased cortisol substantially. However, this trial was acute dosing only — there are no published long-term trials of Ipamorelin examining functional outcomes.

Hexarelin has been studied more extensively because it showed promise for cardiovascular applications beyond growth hormone release. Multiple trials in the 2000s examined its effects in heart failure and post-myocardial infarction, with mixed results. The growth hormone-stimulating doses are similar to other secretagogues (around 2 mcg/kg), but desensitization occurs rapidly — within 2-4 weeks of daily dosing, the growth hormone response attenuates significantly. This tachyphylaxis is less pronounced with Ipamorelin.

MK-677 has the most extensive human trial data of any compound in this class because oral bioavailability made it attractive for pharmaceutical development. A 1998 study in healthy older adults (n=32) showed that 25 mg daily for 2 weeks increased mean 24-hour growth hormone concentration by approximately 97% and IGF-1 levels by 60%. A longer 2-year trial in elderly adults (n=65) found that 25 mg daily increased lean mass by approximately 1.1 kg and decreased fat mass, though functional outcomes like strength did not improve significantly. Side effects included increased appetite, transient mild lower extremity edema, and mild elevations in fasting glucose. Several trials were halted because of concerns about glucose handling.

For all these compounds, the critical evidence gap is long-term safety and efficacy data in healthy adults using them for body composition or performance-related outcomes. Most trials were conducted in populations with pathology (growth hormone deficiency, HIV lipodystrophy, aging-related frailty) over weeks to months, not years. There are no controlled trials examining effects on muscle strength, athletic performance, or cognition in healthy trained individuals.

Research Dosing Parameters from Published Pharmacokinetics and Trials

Dosing for growth hormone peptides varies widely based on compound, administration route, and study population. The following ranges are drawn from published human trials and should be considered starting points for research purposes only.

Sermorelin: 1-2 mcg/kg subcutaneous before bed in most trials. At 70 kg bodyweight, this translates to approximately 70-140 mcg. Typically administered once daily. Half-life is approximately 10-20 minutes after subcutaneous injection, so effects are relatively acute.

Mod GRF 1-29: Pharmacokinetic studies used 1-2 mcg/kg subcutaneous, typically administered 1-3 times daily due to the ~30-minute half-life. Common research protocols use 100 mcg per dose. Administered in combination with a secretagogue in many protocols to amplify the pulse.

CJC-1295 with DAC: The original pharmaceutical trials used 30-90 mcg/kg once weekly. At 70 kg, this is approximately 2.1-6.3 mg per week. More recent research protocols often use 1-2 mg twice weekly. The long half-life means dosing frequency can be reduced significantly compared to shorter-acting analogs.

GHRP-2 and GHRP-6: 0.5-1.5 mcg/kg subcutaneous, 1-3 times daily in trials. Typical per-dose range: 50-150 mcg. Half-life is approximately 20-30 minutes, so effects are pulsatile. Administered on an empty stomach (growth hormone release is blunted by elevated glucose or fatty acids).

Ipamorelin: Research protocols commonly use 200-300 mcg subcutaneous, 1-3 times daily. The half-life is approximately 2 hours, which is longer than other secretagogues but still requires multiple daily doses for sustained effect.

Hexarelin: 2 mcg/kg subcutaneous was the standard dose in cardiovascular trials, roughly 100-150 mcg for a 70 kg individual. Desensitization limits utility beyond 2-4 weeks of continuous daily dosing. Some protocols use intermittent dosing (e.g., 5 days on, 2 days off) to mitigate tachyphylaxis, but this is not well-validated in controlled studies.

MK-677: 25 mg orally once daily is the most studied dose. Lower doses (10 mg) were examined in some trials but produced smaller increases in IGF-1. It can be taken with or without food. Half-life is approximately 4-6 hours, but IGF-1 elevation persists for 24 hours due to downstream effects.

Stability considerations: Most peptides in this class are supplied as lyophilized powder and reconstituted with bacteriostatic water. Once reconstituted, Sermorelin and Mod GRF 1-29 are generally stable refrigerated for 2-4 weeks. CJC-1295 with DAC is more stable due to albumin binding. All peptides should be stored at 2-8°C after reconstitution and protected from light. Freezing reconstituted peptides is not recommended, as freeze-thaw cycles can degrade the peptide chain.

Drug interactions are not extensively documented because these are not FDA-approved therapies (with the exception of Tesamorelin in a narrow indication). However, compounds that affect glucose metabolism (metformin, insulin, GLP-1 agonists) could theoretically interact, as growth hormone is a counter-regulatory hormone that increases blood glucose. Combining multiple growth hormone secretagogues does not appear to produce additive growth hormone release beyond a ceiling — there's a maximal pituitary response regardless of dose escalation.

FAQ

Q: What's the difference between CJC-1295 with DAC and Mod GRF 1-29?

CJC-1295 with DAC has a Drug Affinity Complex that binds serum albumin, extending the half-life to approximately 6-8 days. Mod GRF 1-29 (often called CJC-1295 without DAC) lacks this modification and has a half-life of around 30 minutes. The DAC version produces sustained baseline growth hormone elevation; the non-DAC version produces shorter, more physiological pulses. Most researchers now use Mod GRF 1-29 in combination with a secretagogue like Ipamorelin to create large but transient growth hormone spikes.

Q: Do growth hormone peptides require cycling to remain effective?

For GHRH analogs like Sermorelin, Mod GRF, and CJC-1295, there is minimal evidence of receptor desensitization with continuous use. For secretagogues, Hexarelin shows clear tachyphylaxis within 2-4 weeks, while Ipamorelin appears to maintain responsiveness longer. MK-677 shows sustained IGF-1 elevation over months in published trials without loss of effect. Most research protocols do not cycle GHRH analogs, but some cycle secretagogues empirically, though this practice is not supported by controlled human data.

Q: Can growth hormone peptides be combined, and does it increase effectiveness?

Yes. Combining a GHRH analog with a secretagogue produces significantly larger growth hormone pulses than either alone — this has been demonstrated in multiple human studies since the 1990s. The mechanisms are complementary: GHSR1a activation primes the pituitary, and GHRH receptor activation triggers release. Common pairings include Mod GRF 1-29 with Ipamorelin or GHRP-2. However, combining two secretagogues does not produce additive effects due to a ceiling on pituitary response.

Q: What blood work should be monitored when using growth hormone peptides?

IGF-1 is the most direct marker of growth hormone axis activity and should be measured at baseline and periodically during use. Fasting glucose and hemoglobin A1c should be monitored because growth hormone is a counter-regulatory hormone that can impair insulin sensitivity. Lipid panels may show changes (typically decreased LDL, variable effects on triglycerides). Thyroid function (TSH, free T3, free T4) is worth checking because growth hormone can affect thyroid hormone conversion. Prolactin can be elevated by some secretagogues, particularly GHRP-6.

Q: What is the evidence quality for growth hormone peptides in healthy adults without growth hormone deficiency?

Limited. Most controlled trials enrolled populations with pathology: growth hormone deficiency, HIV lipodystrophy, frailty in the elderly. Tesamorelin has Phase III data in HIV patients. MK-677 has the most data in healthy older adults, showing increases in lean mass but no functional strength gains over 2 years. For compounds like Ipamorelin and Mod GRF 1-29, there are no large long-term trials in healthy adults. The mechanistic rationale is sound — they do increase growth hormone and IGF-1 in short-term studies — but efficacy and safety over years in non-deficient individuals remains incompletely characterized.

---

Growth hormone peptides are research compounds that should only be used under appropriate research conditions. The information provided here is for educational purposes and does not constitute medical advice. Individuals considering use should consult qualified healthcare providers and understand that most compounds in this class are not FDA-approved for body composition or performance applications.